Routine defunctioning stoma after chemoradiation and total mesorectal excision: A single-surgeon experience

Table 1 Clinical demographics (n = 62) n (%)

Variable
Age (yr) (mean ± SD)	58.7 ± 12.8
Gender (male/female)	40/22 (64.5/35.5)
Distance of tumor from anal verge (cm) (median, range)	5 (3-6)
Pre-treatment stage
cT2/T3/T4	17/42/3 (27.4/67.7/4.8)
cN0/cN1/N2	41/16/5 (66.1/25.8/8.1)
Tumor response to CRT (tumor size reduction)1
100% response	8 (12.9)
50%-99%	22 (35.5)
< 50%	32 (51.6)
Toxicity of neoadjuvant CRT
Skin2	1 (1.6)
Nausea/vomiting2	7 (11.3)
Diarrhea3 (Grade II/Grade III)	20/1 (32.3/1.6)
Hematological toxicity	0
Adjuvant chemotherapy	57 (91.9)

¹Evaluated by digital examination and computed tomography;

²Grade I-II;

³Grade I-III. CRT: Chemoradiation therapy.